Developer docs
API playgroundTry for free, no card

Search company profiles

Stix

Full company profile

uuid0000gv1

Namestring
Stix
Websiteurl
getstix.co
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Stix is a female-founded, Philadelphia-based consumer health company founded in 2018 that develops women's health products supported by educational content and community resources aimed at women making informed health decisions. The company markets itself as a "no-judgment health brand," combining product offerings with content and community rather than focusing on a single SKU; however, specific product details have remained undisclosed across public sources, with the most recent (April 2022) funding round earmarked for development of a new women's health product. Co-founded by Cynthia Plotch and Jamie Norwood, Stix has positioned itself in the direct-to-consumer women's health vertical with a brand identity centered on female founders and accessibility.

The company operates as a private, for-profit venture-backed startup with 11-50 employees. Its business model and pricing are not publicly disclosed; the company website (getstix.co) currently redirects to Siemens Healthineers content returning 404 errors, indicating the original brand web presence is no longer active under the Stix name. No distribution channels, marketing channels, customer logos, or revenue figures are disclosed in available sources.

Stix has raised approximately $6.38 million cumulatively across four funding rounds between June 2019 and April 2022. Investors include Resolute Ventures and SWAT Equity Partners (co-leading the two most recent rounds), as well as (ERA) Entrepreneurs Roundtable Accelerator, 1745 Ventures, Fab Co-Creation Studio Ventures, Founders Factory, Overeasy Ventures, Rogue Women's Fund, VamosVentures, Bullish, Chaos Ventures, and Umami Capital — a notable concentration of women-focused and consumer-oriented funds. No acquisitions, partnerships, patents, regulatory actions, leadership changes, or subsequent funding rounds are disclosed in the input data after April 2022.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
women's health products, feminine care products, consumer health brand, personal wellness products, women's wellness brand
Industry3 codes
1Women’s Health Supplements (Prenatal, Menopause, Hormonal)
CodeCRADAGAKPrimaryYes
2Women’s Health & Reproductive Specialty Pharmaceuticals
CodeHLAIACANPrimaryNo
3Menstrual Pain Relief & Period Care Supplements
CodeCRABAIAJPrimaryNo
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Women's Health Products
Social media profiles1 record
Cost components5 values
Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Stix is a female-founded, no-judgment women's health brand based in Philadelphia that combines products, content, and community to help women make informed health decisions. The company was developing a new women's health product funded by a $1.48 million capital raise in April 2022, with specific product details remaining undisclosed at the time of the announcement.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Stix is a women's health company that raised $1.48 million in April 2022 to develop a new women's health product. Specific product details are currently undisclosed. The company website (getstix.co) redirects to Siemens Healthineers content, suggesting a potential acquisition or domain redirect.

Product and service1 record
1Women's Health Products
CategoryWomen's Health Products
Description

Stix's line of no-judgment women's health products, targeted at individual women seeking trusted, destigmatized health solutions. Specific product SKUs and details were undisclosed as of April 2022, when the company raised $1.48 million to develop a new women's health product offering.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Hims & Hers is a scaled consumer telehealth and health products platform selling OTC and prescription treatments directly to consumers. It competes with Stix for the same women's health DTC wallet and offers a much broader portfolio, making it a broad incumbent in the adjacent consumer health space Stix targets.

TypeDirect peer
Description

Wisp is a women's health brand offering telehealth consultations and at-home treatments for UTIs, yeast infections, herpes, and other conditions — closely mirroring Stix's original women's health product mix and direct-to-consumer model.

TypeDirect peer
Description

Tia operates a women's health clinic and care platform delivering integrated gynecological, primary, and mental health services. It is comparable to Stix as a female-founded women's health brand pursuing both physical product and clinical care approaches.

TypeDirect peer
Description

Maven Clinic is a virtual women's and family health platform covering fertility, maternity, and postpartum care. It competes with Stix in women's health and has overlapping target customers and a similar digital-first delivery model.

TypeDirect peer
Description

Kindbody is a fertility and women's health company offering virtual care and clinic-based services. It overlaps Stix in reproductive and women's health consumer segments and follows a similar hybrid digital/physical model.

TypeDirect peer
Description

Ritual is a women's-focused vitamins and supplements brand selling DTC through subscription. It is directly comparable to Stix's CPG/supplements angle, particularly for prenatal and women's health formulations.

TypeDirect peer
Description

The Honey Pot Company is a female-founded feminine care brand offering washes, wipes, and menstrual products through DTC and retail channels. It is comparable to Stix as a women's personal care/wellness CPG brand targeting similar end consumers.

TypeDirect peer
Description

LOLA is a women's health CPG brand best known for organic tampons and feminine care products, selling DTC and through retail. It shares Stix's positioning as a no-judgment, women-led consumer brand in feminine wellness.

TypeDirect peer
Description

Nurx is a telehealth platform providing prescription and at-home testing services for reproductive and sexual health. It overlaps directly with Stix's historical STI, contraception, and at-home testing offerings and target customers.

TypeDirect peer
Description

Ro operates consumer health brands including Rory, a women's health vertical focused on perimenopause and menopause. It competes with Stix for women's health consumer share and benefits from Ro's broader telehealth infrastructure.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stix

Women's Health Productsgetstix.co

What Stix does

Stix is a female-founded, Philadelphia-based consumer health company founded in 2018 that develops women's health products supported by educational content and community resources aimed at women making informed health decisions. The company markets itself as a "no-judgment health brand," combining product offerings with content and community rather than focusing on a single SKU; however, specific product details have remained undisclosed across public sources, with the most recent (April 2022) funding round earmarked for development of a new women's health product. Co-founded by Cynthia Plotch and Jamie Norwood, Stix has positioned itself in the direct-to-consumer women's health vertical with a brand identity centered on female founders and accessibility.

The company operates as a private, for-profit venture-backed startup with 11-50 employees. Its business model and pricing are not publicly disclosed; the company website (getstix.co) currently redirects to Siemens Healthineers content returning 404 errors, indicating the original brand web presence is no longer active under the Stix name. No distribution channels, marketing channels, customer logos, or revenue figures are disclosed in available sources.

Stix has raised approximately $6.38 million cumulatively across four funding rounds between June 2019 and April 2022. Investors include Resolute Ventures and SWAT Equity Partners (co-leading the two most recent rounds), as well as (ERA) Entrepreneurs Roundtable Accelerator, 1745 Ventures, Fab Co-Creation Studio Ventures, Founders Factory, Overeasy Ventures, Rogue Women's Fund, VamosVentures, Bullish, Chaos Ventures, and Umami Capital — a notable concentration of women-focused and consumer-oriented funds. No acquisitions, partnerships, patents, regulatory actions, leadership changes, or subsequent funding rounds are disclosed in the input data after April 2022.

Stix firmographics

Firmographics
Name
Stix
Website
https://getstix.co
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Stix industry classification

Industry
Product category
Women's Health Products
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK)
akta.pro secondary industries
Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Menstrual Pain Relief & Period Care Supplements (CRABAIAJ)

Keywords

  • Women's health products
  • Feminine care products
  • Consumer health brand
  • Personal wellness products
  • Women's wellness brand

Where Stix is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

Stix business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain

Stix product offering

Product offering

Core offering

Stix is a female-founded, no-judgment women's health brand based in Philadelphia that combines products, content, and community to help women make informed health decisions. The company was developing a new women's health product funded by a $1.48 million capital raise in April 2022, with specific product details remaining undisclosed at the time of the announcement.

Product overview

Stix is a women's health company that raised $1.48 million in April 2022 to develop a new women's health product. Specific product details are currently undisclosed. The company website (getstix.co) redirects to Siemens Healthineers content, suggesting a potential acquisition or domain redirect.

Differentiator

Problem solved

Functional benefit

Products and services

  • Women's Health Products Stix's line of no-judgment women's health products, targeted at individual women seeking trusted, destigmatized health solutions. Specific product SKUs and details were undisclosed as of April 2022, when the company raised $1.48 million to develop a new women's health product offering.

Companies that use Stix

Customer profile

Segments1 record

Ideal customer profiles1 record

Stix technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Stix partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Stix competitors and assessment

Company assessment

Broad incumbents

  • Hims & Hers Health: Hims & Hers is a scaled consumer telehealth and health products platform selling OTC and prescription treatments directly to consumers. It competes with Stix for the same women's health DTC wallet and offers a much broader portfolio, making it a broad incumbent in the adjacent consumer health space Stix targets.

Direct peers

  • Wisp: Wisp is a women's health brand offering telehealth consultations and at-home treatments for UTIs, yeast infections, herpes, and other conditions — closely mirroring Stix's original women's health product mix and direct-to-consumer model.
  • Tia: Tia operates a women's health clinic and care platform delivering integrated gynecological, primary, and mental health services. It is comparable to Stix as a female-founded women's health brand pursuing both physical product and clinical care approaches.
  • Maven Clinic: Maven Clinic is a virtual women's and family health platform covering fertility, maternity, and postpartum care. It competes with Stix in women's health and has overlapping target customers and a similar digital-first delivery model.
  • Kindbody: Kindbody is a fertility and women's health company offering virtual care and clinic-based services. It overlaps Stix in reproductive and women's health consumer segments and follows a similar hybrid digital/physical model.
  • Ritual: Ritual is a women's-focused vitamins and supplements brand selling DTC through subscription. It is directly comparable to Stix's CPG/supplements angle, particularly for prenatal and women's health formulations.
  • The Honey Pot Company: The Honey Pot Company is a female-founded feminine care brand offering washes, wipes, and menstrual products through DTC and retail channels. It is comparable to Stix as a women's personal care/wellness CPG brand targeting similar end consumers.
  • LOLA: LOLA is a women's health CPG brand best known for organic tampons and feminine care products, selling DTC and through retail. It shares Stix's positioning as a no-judgment, women-led consumer brand in feminine wellness.
  • Nurx: Nurx is a telehealth platform providing prescription and at-home testing services for reproductive and sexual health. It overlaps directly with Stix's historical STI, contraception, and at-home testing offerings and target customers.
  • Ro (Rory): Ro operates consumer health brands including Rory, a women's health vertical focused on perimenopause and menopause. It competes with Stix for women's health consumer share and benefits from Ro's broader telehealth infrastructure.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Stix social profiles

Digital presence

Stix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stix leadership team

Management profile

Number of profiles

Profiles2 records

Stix funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stix

What does Stix do?

Stix is a female-founded, no-judgment women's health brand based in Philadelphia that combines products, content, and community to help women make informed health decisions. The company was developing a new women's health product funded by a $1.48 million capital raise in April 2022, with specific product details remaining undisclosed at the time of the announcement.

Is Stix a public or private company?

Stix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stix founded?

Stix was founded in 2018. It employs 11 to 50 people.

Where is Stix based?

Stix is headquartered in Philadelphia, United States, in the North America region.

Who are Stix's main competitors?

Hims & Hers Health is listed as a broad incumbent. Direct peers are Wisp, Tia, Maven Clinic, Kindbody, Ritual, The Honey Pot Company, LOLA, Nurx and Ro (Rory).

Does Stix have an API?

No public API is recorded for Stix.

What industry is Stix in?

Stix's product category is Women's Health Products. Its primary akta.pro industry code is CRADAGAK, Women’s Health Supplements (Prenatal, Menopause, Hormonal), with a secondary code of HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pegnCVM edita resolução para aumentar controles contra lavagem de dinheiroGPA sold its stake in Stix to RD Saúde Empresas. In the financial markets, Ibovespa rose and the dollar remained stable ahead of a U.S. holiday; treasury futures increased amid a weak payroll report, with oil prices also up.24-7 Press ReleaseShuja Rabbani Positions Human Resources as a Strategic Force for the GCC's Next Era of Business TransformationShuja Rabbani, a GCC-based HR practitioner, is positioning human resources as a strategic force for business transformation. His Berkeley capstone project examined HR's role in geopolitical crisis, and he advocates for AI adoption and psychological safety. He is emerging as a thought leader on workforce intelligence and organizational resilience.Business InsiderThe economy, funding, and 3 other small-business challenges entrepreneurs will face in 2023, according to foundersInsider surveyed 68 founders on their 2023 predictions, with top challenges centered on an unstable economy affecting funding, sales, and marketing. Cynthia Plotch, CEO of Stix, said many founders will feel uncertain in these tumultuous times.Business InsiderDTC brands are raising millions to make emergency contraception more accessible in a post-Roe America. One investor says women's health 'is where fintech was 10 years ago.'Stix launched Restart, a $38 morning-after pill, in June ahead of the Supreme Court's Roe v. Wade reversal. The company raised $6.4 million since 2019 and is seeking more funds, while investors see women's health as a high-growth opportunity.Business Insider'Your birth control is next': Health startups are using the repeal of Roe v. Wade in new ad campaigns for emergency contraceptionDigital health startups Favor and Stix launched ad campaigns for emergency contraception after the Supreme Court overturned Roe v. Wade. The ads warn that birth control access is next, and some companies are stockpiling pills, with CVS limiting purchases. Emergency contraception remains legal nationwide, though 12 states allow providers to refuse it.FinSMEsStix Raises $3.5M in Seed FundingStix, a Philadelphia-based women's health company, raised $3.5M in seed funding co-led by Resolute Ventures and SWAT Equity Partners. The funds will expand its physical product line into new health stages and develop its digital education platform. The company, founded in 2019, now offers ovulation tests, prenatal supplements, and UTI products.